Ecogene-21

Running trials

• Recruiting

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  NCT07684235· Phase 3· Source

• Active, not recruiting

  A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

  NCT07662122· Phase 2· Source

• Active, not recruiting

  A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Phase 2· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Source

• Recruiting

  A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  NCT06897475· Phase 2· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

  NCT04083339· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Type 2 diabetes2 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Source

• Completed

  Study of INV-202 in Patients With Obesity and Metabolic Syndrome

  NCT05891834· Phase 2· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Source

• Completed

  A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

  NCT05694260· Phase 2· Source

• Completed

  Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

  NCT05327127· Phase 2· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  LOWER: Lomitapide Observational Worldwide Evaluation Registry

  NCT02135705· Source